Here is a fact about the American healthcare system that everyone accepts and almost nobody enjoys: before a doctor can do many of the things a doctor recommends, somebody has to ask permission. The technical name for asking permission is prior authorization, and it is a process in which a physician who has already decided what a patient needs submits paperwork to an insurance company, which then decides whether it agrees. This takes time. It employs a great many people. It generates faxes. It is, by most accounts, one of the more reviled workflows in modern medicine, and it is exactly the problem that basys.ai decided to make its business.
You could build a company around the flashy end of healthcare AI - reading scans, discovering drugs, diagnosing rare disease. basys.ai went the other way. It picked utilization management, payment integrity, and the permission-slip machinery of prior authorization, on the theory that the least glamorous problems are frequently the most valuable ones. When a workflow is expensive, universally hated, and buried in administrative cost, "we automate the boring part" turns out to be a fairly compelling pitch.
The company was founded in 2022 by Amber Nigam and Jie Sun, who met in Harvard's health data science program. Nigam, the CEO, is a repeat founder who had already built and exited an AI startup before going back to school - which is a slightly unusual career arc, because most people do the degree first and the startup second. The version where you sell a company and then go get the credential suggests someone who was less interested in the credential and more interested in the specific thing the credential taught: how to do data science on health data without setting anything on fire.
"The engine is trained on extensive Joslin Diabetes Center and Mayo Clinic's longitudinal data of more than 10 million patients - which translates to flattening the cost curve."
What it actually does
The clever part of basys.ai is less about the AI being smart and more about what the AI is smart at. When a prior authorization request arrives, the system pulls the relevant patient information - documentation, charts, lab reports - and assembles a longitudinal picture of that patient's health. Separately, it has encoded the payer's own coverage policies: the actual rules about what is covered, when, and under what clinical conditions. Then it compares the two. Does this patient, given this history, meet this payer's criteria for this treatment? The output is a decision, rendered in minutes rather than days.
Crucially, the system does not just say yes or no. It explains itself in plain language, with hyperlinks to the specific policy criteria and clinical notes that drove the decision. This is the design choice that separates basys.ai from a black box: a payer, a provider, and a patient can all read the same rationale and follow the same logic. In an industry where coverage denials often feel like edicts from an opaque bureaucracy, "here is exactly why, and here is the rule we applied" is a genuinely different product.
There is also a shrewd bit of go-to-market engineering baked into the approach. Because the system encodes the payer's policy rather than requiring wholesale access to an insurer's or doctor's sensitive data, basys.ai says it can stand up in weeks rather than the roughly one year that healthcare integrations notoriously consume. In enterprise healthcare, the graveyard is full of good products that died waiting on an integration timeline. Compressing that timeline is not a minor feature - it is frequently the difference between a signed contract and a stalled pilot.
The data pedigree
The engine was trained on longitudinal data covering more than 10 million patients from Joslin Diabetes Center and Mayo Clinic. In healthcare AI, where your training data comes from is not a footnote - it is a large part of the credibility. A model trained on institutions clinicians already trust starts a few steps ahead of one trained on scraped, anonymous, provenance-unknown records. It is not a coincidence that Mayo Clinic is both a data source and, as it happens, an investor.
Who's paying attention
In 2023 the company raised an oversubscribed $2.4 million pre-seed round led by Nina Capital, with a backer list that reads like a healthcare heavyweight roll call: Eli Lilly's venture arm, Mayo Clinic, Two Lanterns Venture Partners, Asset Management Ventures, and Chaac Ventures. Pharma money and a top-tier clinical system on the same cap table is a useful signal - these are strategic investors who understand the workflow being automated and have every reason to scrutinize it.
Then, in 2025, basys.ai did something more interesting than raise a splashy follow-on: it stacked distribution. Rather than trying to sell every health plan directly, the company partnered with companies already inside its customers' walls. It teamed with MedeAnalytics on utilization management aimed at improving medical loss ratio, with Smart Data Solutions to reach health plans and third-party administrators, and with RELI Group to push into federal health programs - co-developing SureReview, an AI-powered medical record review tool slated for a 2026 launch. Around the same time, CMS named basys.ai a national finalist in its Crushing Fraud, Waste, and Abuse Challenge, a notable credential for a company that wants to work with government health programs.
None of this makes basys.ai a sure thing. It is a roughly 20-person company taking on the vast administrative machinery of American health plans, in a category with well-funded competitors and incumbents who do not intend to be disrupted quietly. But the strategy is coherent, the problem is real, and the discipline is visible: it does three related things - prior authorization, utilization management, payment integrity - and it does not pretend to do everything. In a market drunk on "end-to-end platforms," a company that says "these specific workflows, done well, with the reasoning shown" is making a quieter and more defensible argument than most.